Study of two forms of a pancreatic cancer drug
Part of Cancer clinical trials.
This trial compares two different versions of an investigational drug for metastatic pancreatic cancer to see how they work in the body and if they are safe. It may help find a better way to give the drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic cancer that has spread to other parts of the body (metastatic).
- You are able to use effective birth control for at least 6 months after the last dose of the study drug.
- You agree to avoid certain foods (like grapefruit) for a few days before and during the study.
- You have not taken other experimental drugs in the last 4 weeks.
- You can give your written consent to participate.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. It aims to see if the drug can shrink tumors and improve outcomes.
This trial tests personalized therapies for people with advanced pancreatic cancer that has spread or cannot be removed. It aims to find the best treatment based on your tumor's unique features.
This trial tests a new drug combined with other treatments for advanced pancreatic cancer. It aims to see if the combination can help people whose cancer has a specific genetic change called RAS mutation.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This trial tests three new targeted drug combinations for pancreatic cancer that has a specific genetic change (KRAS G12D). They are comparing the study drug alone versus combining it with other investigational drugs to see which works better.
This Phase 2 study compares two chemotherapy combinations to treat metastatic pancreatic cancer that has progressed after gemcitabine (with or without Abraxane). It aims to see which combination works better and is tolerable for people with measurable disease.
Hear when a new Metastatic Adenocarcinoma of the Pancreas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.